Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Fineline Cube Dec 11, 2025
Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Fineline Cube Dec 11, 2025
Company Deals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Fineline Cube Dec 11, 2025
Company Deals

Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership

Fineline Cube Dec 11, 2025
Company Deals

D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally

Fineline Cube Dec 10, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Fineline Cube Dec 11, 2025
Company Drug

Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy

Fineline Cube Dec 11, 2025
Company Deals

Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development

Fineline Cube Oct 30, 2025

China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) and U.S. biotech firm Abalone Bio signed...

Policy / Regulatory

MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue

Fineline Cube Oct 30, 2025

The 2025 National Medical Insurance (MediCare) Negotiation kicked off at 8:30 AM, marking the start of...

Company Deals

Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million

Fineline Cube Oct 30, 2025

Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...

Company Drug

Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma

Fineline Cube Oct 30, 2025

Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody‑drug conjugate (ADC) Becotatug Vedotin (MGR003)...

Company Deals

Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma

Fineline Cube Oct 30, 2025

Eli Lilly & Co. (NYSE: LLY) today announced a groundbreaking partnership with NVIDIA to build...

Company Drug

Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody

Fineline Cube Oct 30, 2025

Shanghai Ark Biopharmaceutical Co., Ltd. (ARK) today announced the official start of a Phase II clinical...

Company

NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ

Fineline Cube Oct 30, 2025

NovaBridge Biosciences (formerly I‑Mab, NASDAQ: IMAB) announced today that its corporate name change is now...

Others

Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer

Fineline Cube Oct 30, 2025

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA:  688180) announced today that its programmed death‑1...

Company Drug

InnoCare Announces First Patient Dosing of ICP‑B794, a Novel B7‑H3 Targeting ADC

Fineline Cube Oct 30, 2025

China‑based InnoCare Pharma Limited (SHA: 688428, HKG: 9969) today disclosed that its self‑developed antibody‑drug conjugate...

Policy / Regulatory

National Health Commission Unveils Fourth Drug List for Generic Development

Fineline Cube Oct 30, 2025

The National Health Commission (NHC) today released its fourth catalogue of medicines earmarked for generic...

Company

BioMarin Cuts 2027 Revenue Target Amid Voxzogo Competition

Fineline Cube Oct 30, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced during its third‑quarter earnings call that it no longer...

Company

GSK Reports Strong Q3 2025 Results, Beats Forecasts with 8% Revenue Growth

Fineline Cube Oct 29, 2025

UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) delivered a compelling Q3 2025 earnings report that...

Company Drug

Sihuan Pharmaceutical Secures Fast‑Track Designation for NG‑350A in U.S. Rectal Cancer Treatment

Fineline Cube Oct 29, 2025

Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced today that NG‑350A, a clinical‑stage oncolytic immunotherapy...

Company Legal / IP

YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China

Fineline Cube Oct 29, 2025

Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...

Company Deals

BioRay Pharmaceutical Co., Ltd. Signs MENA‑Wide Licensing Deal With Saudi Tabuk Pharmaceutical Manufacturing

Fineline Cube Oct 29, 2025

BioRay Pharmaceutical Co., Ltd. today announced the execution of a comprehensive license, supply, and commercialization...

Company Deals

IASO Biotherapeutics Partners with GC Cell to Advance Equecabtagene Autoleucel CAR‑T Therapy in South Korea

Fineline Cube Oct 29, 2025

IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...

Company Deals

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

Fineline Cube Oct 29, 2025

GlaxoSmithKline plc (GSK, NYSE: GSK) and Empirico Ltd. today announced a global exclusive licence agreement...

Company Deals

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development

Fineline Cube Oct 29, 2025

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) today announced the signing of strategic Memoranda of...

Company Deals

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N

Fineline Cube Oct 29, 2025

Qyuns Therapeutics Co., Ltd. (HKG: 2509) today announced a global exclusive collaboration and licensing agreement with F. Hoffmann‑La...

Company Drug

Jiangsu Aidea Secures Approval to Launch ADC118 Tablets in China, First Domestic HIV Integrase FDC

Fineline Cube Oct 29, 2025

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHA: 688488) announced today that its self‑developed Class 1 anti‑HIV drug, ADC118...

Posts pagination

1 … 17 18 19 … 596

Recent updates

  • Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
  • Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension
  • Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
  • Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
  • Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Company Drug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Company Deals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Company Deals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.